Experts Split Sharply Over Experimental Alzheimer’s Drug

December 5, 2019

(ABC News) – A company that claims to have the first drug to slow mental decline from Alzheimer’s disease made its case to scientists Thursday but left them sharply divided over whether there‚Äôs enough evidence of effectiveness for the medicine to warrant federal approval. Excitement and skepticism have surrounded aducanumab since its developers stopped two studies earlier this year because it didn’t seem to be working, then did a stunning about-face in October and said new results suggest it was effective at a high dose.